RENATA GOMES SANCHES VERARDINO

(Fonte: Lattes)
Índice h a partir de 2011
1
Lattes
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Coração, Hospital das Clínicas, Faculdade de Medicina

Filtros

Limpar filtros

Configurações

Resultados de Busca

Agora exibindo 1 - 3 de 3
  • conferenceObject
    IMPACT OF PREVIOUS HYPERTENSIVE DISORDER DURING PREGNANCY ON ANTHROPOMETRIC MEASUREMENTS, 24-HOUR BLOOD PRESSURE AND ARTERIAL STIFFNESS
    (2021) VERARDINO, Renata; RODRIGUES, Sara; BERGER, Ana; COSTA-HONG, Valeria; MACEDO, Thiago; BAPTISTA, Fernanda; BORTOLOTTO, Maria; FRANCISCO, Rossana; ZUGAIB, Marcelo; BORTOLOTTO, Luiz
  • conferenceObject
    IMPACT OF A MULTIDISCIPLINARY INTERVENTIONAL PROGRAM ON BLOOD PRESSURE CONTROL AND HEALTHY LIFESTYLE ADHERENCE IN PATIENTS WITH HYPERTENSION AND METABOLIC SYNDROME
    (2016) BORTOLOTTO, L.; VERARDINO, R.; SANTOS, R.; IKEDA, E.; GIACCHINI, F.; DUENHAS, A.; LOYOLA, I.; DEROZIER, P.; FONSECA, E.; MARINHO, F.; LOPES, H.
  • article 3 Citação(ões) na Scopus
    Arterial Stiffness in Transgender Men Receiving Long-term Testosterone Therapy
    (2023) CUNHA, Flavia Siqueira; BACHEGA, Tania Aparecida Sanchez; COSTA, Elaine Maria Frade; BRITO, Vinicius Nahime; ALVARES, Leonardo Azevedo; COSTA-HONG, Valeria Aparecida; VERARDINO, Renata Gomes Sanches; SIRCILI, Maria Helena Palma; MENDONCA, Berenice Bilharinho de; BORTOLOTTO, Luiz Aparecido; DOMENICE, Sorahia
    Context: The effects of androgen therapy on arterial function in transgender men (TM) are not fully understood, particularly concerning long-term androgen treatment. Objective: To evaluate arterial stiffness in TM receiving long-term gender-affirming hormone therapy by carotid-femoral pulse wave velocity (cf-PWV). Methods: A cross-sectional case-control study at the Gender Dysphoria Unit of the Division of Endocrinology, HC-FMUSP, Sao Paulo, Brazil. Thirty-three TM receiving intramuscular testosterone esters as regular treatment for an average time of 14 +/- 8 years were compared with 111 healthy cisgender men and women controls matched for age and body mass index. Aortic stiffness was evaluated by cf-PWV measurements using Complior device post-testosterone therapy. The main outcome measure was aortic stiffness by cf-PWV as a cardiovascular risk marker in TM and control group. Results: The cf-PWV after long-term testosterone therapy was significantly higher in TM (7.4 +/- 0.9 m/s; range 5.8-8.9 m/s) than in cisgender men (6.6 +/- 1.0 m/s; range 3.8-9.0 m/s, P <.01) and cisgender women controls (6.9 +/-.9 m/s; range 4.8-9.1 m/s, P =.02). The cf-PWV was significantly and positively correlated with age. Analysis using blood pressure as a covariate showed a significant relationship between TM systolic blood pressure (SBP) and cf-PWV in relation to cisgender women but not to cisgender men. Age, SBP, and diagnosis of hypertension were independently associated with cf-PWV in the TM group. Conclusion: The TM group on long-term treatment with testosterone had higher aging-related aortic stiffening than the control groups. These findings indicate that aortic stiffness might be accelerated in the TM group receiving gender-affirming hormone treatment, and suggest a potential deleterious effect of testosterone on arterial function. Preventive measures in TM individuals receiving testosterone treatment, who are at higher risk for cardiovascular events, are highly recommended.